Based on the information below this appears to be the method by which Neuren develops its new indications for treatment:
Drug repositioning is a promising field in drug discovery that identifies new therapeutic opportunities for existing drugs. In order to circumvent some of the most expensive drug discovery processes, companies pursue this strategy to increase their productivity (new drugs to market) by reducing the discovery and development timeline. This decreases the overall cost of bringing the drug to market because the safety and pharmacokinetic profiles of the repositioned candidates are already established.The term “drug repositioning” has been used interchangeably with “drug repurposing” or “drug reprofiling.” All these expressions are relatively synonymous for describing the process that seeks to discover new applications for an existing drug that were not previously referenced and not currently prescribed or investigated.
NNZ-2591 is a drug being repurposed to treat a number of conditions, including Angelman syndrome, Prader-Willi syndrome (PWS), and Pitt-Hopkins syndrome. NNZ-2591 is a synthetic analog of cyclic glycine-proline (cGP), a metabolite of insulin-like growth factor 1 (IGF-1). IGF-1 is important for brain development and response to injury. Kens
NEU Price at posting:
$11.25 Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)